JMP Securities analyst Liisa Bayko was out with a research note on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), after the biotech company released uneventful second-quarter results …
Analyst Michelle Gilson of Oppenheimer feels confident about eteplirsen, a pipeline drug for Sarepta Therapeutics Inc (NASDAQ:SRPT), even though Santhera, a competitor of …
